Rekvina Laboratories Ltd

Rekvina Laboratories Limited has announced the appointment of Mr. Subrata Samanta as the Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the company. The appointment was approved by the Board of Directors at a meeting held on October 7, 2026, and is effective from the same date. Mr. Samanta brings over 20 years of experience in finance and costing, having previously worked with prominent organizations like Lupin Pharmaceuticals, Glenmark Pharmaceuticals, and Intas Pharmaceuticals. He holds an M.Com degree and is an Associate Cost and Management Accountant (ACMA).

Rekvina Laboratories Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure will be effective from October 1, 2026, and will continue until 48 hours after the declaration of the company's financial results for the quarter and half-year ended September 30, 2026. The specific date for the Board Meeting to review and approve these financial results will be communicated later. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct.

Rekvina Laboratories Ltd announced that its Board of Directors has noted the resignation of Mr. Amit Shah from the position of Managing Director, effective September 11, 2026. The resignation is attributed to personal reasons and commitments. Additionally, the company has approved a change in its registered office within Vadodara, effective September 23, 2026. The board meeting where these decisions were made commenced at 6:30 pm and concluded at 7:30 pm on September 23, 2026.

Rekvina Laboratories Ltd announced a change in its registered office effective September 23, 2026, relocating within Vadodara. Concurrently, the company's Board of Directors accepted the resignation of Mr. Amit Shah from his position as Managing Director, effective September 11, 2026, citing personal reasons. The board meeting where these decisions were made concluded on September 23, 2026.

Rekvina Laboratories Limited has announced the resignation of Mr. Amit Shah from his positions as Managing Director and Director, effective September 11, 2026. The resignation is attributed to personal reasons and commitments. Mr. Shah has confirmed that there are no other factors influencing his decision. The company has filed the necessary disclosures as per SEBI regulations. The details required under SEBI regulations are enclosed as Annexure-I.

Rekvina Laboratories Ltd held a Board of Directors meeting on September 3, 2026, to approve the Annual Report for FY2025-26 and the notice for the upcoming Annual General Meeting (AGM). Key decisions included approving the AGM notice, the FY25-26 Annual Report, appointing M/s S. Bhattbhatt & Co. as E-voting scrutinizer, and M/s. Hetanshi Shah & Associates as Internal Auditors. The board also noted the resignation of Mr. Deepak Khandelwal as Company Secretary and Compliance Officer, effective September 2, 2026. The 38th AGM is scheduled for September 29, 2026, to adopt the audited financial statements, re-appoint Mrs. Ilaben Pathak as a director, and appoint Mr. Prateek Jain as an Independent Director.

Rekvina Laboratories Ltd announced that its 38th Annual General Meeting (AGM) will be held on September 29, 2026, through an online mode. The meeting will consider and adopt the audited financial statements for the fiscal year 2025-26, along with the Board and Auditor reports. Key agenda items include the re-appointment of Mrs. Ilaben Pathak as a director and the appointment of Mr. Prateek Jain and Mr. Jay Chintan Patel as Independent Directors for a term of five years. The company also noted the resignation of Mr. Deepak Khandelwal as Company Secretary and Compliance Officer, effective September 2, 2026. The Board of Directors met on September 3, 2026, to approve the AGM notice and Annual Report.

Rekvina Laboratories Ltd has disclosed a substantial acquisition of shares by Surbhit Mukesh Shah and associated individuals (Amit Mukesh Shah, Ami Amit Shah, Krima Surbhit Shah). The acquisition involved 49,57,051 shares, comprising 17,45,490 shares acquired through an Open Offer and 32,11,561 shares via Preferential Allotment. Following this, the total holding of the acquirers and Persons Acting in Concert (PACs) stands at 67,02,541 shares. The acquisition was executed through an Open Offer and a Preferential Allotment, with the latter involving a share swap agreement dated March 16, 2026. The total consideration for the preferential allotment was ₹5,55,78,750, and for the open offer was ₹3,01,40,000.

Dhruvalkumar Patel has disclosed a substantial acquisition of 11,12,562 equity shares, representing 10.01% of the total voting capital, in Rekvina Laboratories Limited. The acquisition was executed through a combination of a preferential allotment on August 12, 2026, and an open offer on August 13, 2026. The total consideration for the acquisition amounted to ₹3,01,40,000. Following this acquisition, Dhruvalkumar Patel's holding in Rekvina Laboratories now stands at 10.01%. This disclosure is made in compliance with SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Rekvina Laboratories Limited has responded to stock exchange queries regarding significant price movements in its securities. The company stated it is unaware of any specific information, event, or impending announcement that could be influencing the price, beyond what has already been disclosed. Rekvina confirmed its compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and asserted that no undisclosed price-sensitive information or material events are being withheld. The company attributes the price and volume fluctuations to market-driven factors.